ArticleFrontiers in public health2025
Stage-specific prevalence and progression of sarcopenia among aging hemodialysis patients: a multicenter cross-sectional study.
Article in Frontiers in public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The Link Between Dietary Indices, Sarcopenia, and Clinical Parameters in Diabetic and Non-Diabetic Hemodialysis Patients.Journal of clinical medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: To investigate the stage-specific prevalence and progression mechanisms of sarcopenia in aging patients undergoing maintenance hemodialysis (MHD), and to identify modifiable risk and protective factors relevant to early public health interventions. Methods: This multicenter cross-sectional study enrolled 448 eligible older adults (aged ≧ 60 years) undergoing maintenance hemodialysis (MHD) from three tertiary hospitals in Bengbu, China, between January and April 2025, using convenience sampling. Sarcopenia was classified according to the Asian Working Group for Sarcopenia (AWGS) 2019 criteria. Data on demographics, body composition, nutrition, self-efficacy, physical activity, and inflammation were collected. Logistic regression analyses identified factors associated with sarcopenia onset and progression. Results: Sarcopenia prevalence was 54.0%, with 25.0% at the possible stage, 19.6% confirmed, and 9.4% severe. Key protective factors for sarcopenia onset included female sex, higher basal metabolic rate (BMR), higher Body Mass Index (BMI) and greater self-efficacy (SES6). Risk factors included low physical activity, diabetes, longer dialysis vintage, and malnutrition (MQSGA). Progression to confirmed/severe stages was independently associated with reduced BMI, protein mass, and self-efficacy, along with elevated BMR and physical inactivity. These findings highlight the importance of early screening and personalized preventive strategies in aging MHD populations. Conclusion: Sarcopenia is highly prevalent among older adults receiving MHD, with distinct stage-specific progression patterns. This study identified key modifiable risk and protective factors related to both the onset and progression of sarcopenia. Early detection of possible sarcopenia and timely interventions targeting nutrition, physical activity, and self-efficacy may delay progression and promote healthy aging in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.